Precipio (NASDAQ:PRPO) Shares Pass Above Two Hundred Day Moving Average – Time to Sell?

Precipio, Inc. (NASDAQ:PRPO) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $21.09 and traded as high as $24.08. Precipio shares last traded at $24.08, with a volume of 18,512 shares traded.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Precipio to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Precipio has an average rating of “Sell”.

Precipio Stock Performance

The firm has a fifty day moving average price of $23.57 and a 200 day moving average price of $21.14. The company has a current ratio of 1.27, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06. The firm has a market cap of $42.14 million, a PE ratio of -29.37 and a beta of 1.20.

Institutional Trading of Precipio

A number of hedge funds and other institutional investors have recently made changes to their positions in PRPO. AMH Equity Ltd raised its position in shares of Precipio by 370.1% during the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after buying an additional 103,210 shares during the period. Topline Capital Management LLC acquired a new stake in Precipio during the third quarter worth $1,158,000. Evernest Financial Advisors LLC purchased a new stake in Precipio in the third quarter valued at $374,000. Geode Capital Management LLC lifted its stake in shares of Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 789 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Precipio by 10.7% in the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 1,400 shares during the last quarter. Institutional investors and hedge funds own 10.45% of the company’s stock.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.